Lakshmi Jayashankar

Lakshmi Jayashankar

Auto-generated profile, based on publicly available information

Lakshmi Jayashankar

Columbus Technologies Inc., Contractor to National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
APAdam Penn-Nicholson
Adam Penn-Nicholson
MTMichele Tameris
Michele Tameris
ESErica Smit
Erica Smit
TDTracey A Day
Tracey A Day
MMMunyaradzi Musvosvi
Munyaradzi Musvosvi
MHMark Hatherill
Mark Hatherill

4 September 2018 in npj Vaccines
Verified
Journal Article
Open access
PDF file
RCRhea Coler
Rhea Coler
TDTracey A. Day
Tracey A. Day
RERuth Ellis
Ruth Ellis
FPFranco M. Piazza
Franco M. Piazza
ABAnna Marie Beckmann
Anna Marie Beckmann
CJCasey Johnson
Casey Johnson
Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a fusion protein TB vaccine candidate combined with the Toll-like Receptor 4 agonist adjuvant, GLA-SE. We conducted a phase 1, randomized, double-blind, dose-escalation clinical trial to evaluate two dose levels of the ID93 antigen, administered intramuscularly alone or in combination with two dose levels of the GLA-SE adjuvant, in 60 BCG-naive, QuantiFERON-negative, healthy adults in the US (ClinicalTrials.gov identifier: NCT01599897). When administered as 3 injections, 28 days apart, all dose levels of ID93 alone and ID93 + GLA-SE demonstrated an acceptable safety profile. All regimens elicited vaccine-specific humoral and cellular responses. Compared with ID93 alone, vaccination with ID93 + GLA-SE elicited higher titers of ID93-specific antibodies, a preferential increase in IgG1 and IgG3 subclasses, and a multifaceted Fc-mediated effector function response. The addition of GLA-SE also enhanced the magnitude and polyfunctional cytokine profile of CD4+ T cells. The data demonstrate an acceptable safety profile and indicate that the GLA-SE adjuvant drives a functional humoral and T-helper 1 type cellular response.

10 April 2015 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
RCRhea Coler
Rhea Coler
MDMalcolm Duthie
Malcolm Duthie
KHKimberly A Hofmeyer
Kimberly A Hofmeyer
JGJeffery Guderian
Jeffery Guderian
LJLakshmi Jayashankar
Lakshmi Jayashankar
SRSteven G Reed
Steven G Reed
Key antigens of Leishmania species identified in the context of host responses in Leishmania‐exposed individuals from disease‐endemic areas were prioritized for the development of a subunit vaccine against visceral leishmaniasis (VL), the most deadly form of leishmaniasis. Two Leishmania proteins—nucleoside hydrolase and a sterol 24‐c‐methyltransferase, each of which are protective in animal models of VL when properly adjuvanted— were produced as a single recombinant fusion protein NS (LEISH‐F3) for ease of antigen production and broad coverage of a heterogeneous major histocompatibility complex population. When formulated with glucopyranosyl lipid A‐stable oil‐in‐water nanoemulsion (GLA‐SE), a Toll‐like receptor 4 TH1 (T helper 1) promoting nanoemulsion adjuvant, the LEISH‐F3 polyprotein induced potent protection against both L. donovani and L. infantum in mice, measured as significant reductions in liver parasite burdens. A robust immune response to each component of the vaccine with polyfunctional CD4 TH1 cell responses characterized by production of antigen‐specific interferon‐γ, tumor necrosis factor and interleukin‐2 (IL‐2), and low levels of IL‐5 and IL‐10 was induced in immunized mice. We also demonstrate that CD4 T cells, but not CD8 T cells, are sufficient for protection against L. donovani infection in immunized mice. Based on the sum of preclinical data, we prepared GMP materials and performed a phase 1 clinical study with LEISH‐F3+GLA‐SE in healthy, uninfected adults in the United States. The vaccine candidate was shown to be safe and induced a strong antigen‐specific immune response, as evidenced by cytokine and immunoglobulin subclass data. These data provide a strong rationale for additional trials in Leishmania‐endemic countries in populations vulnerable to VL.

1 January 2016 in Vaccine
Verified
Journal Article
Closed access
MSMarilia Santini-Oliveira
Marilia Santini-Oliveira
RCRhea N. Coler
Rhea N. Coler
JPJuçara Parra
Juçara Parra
VVValdilea Veloso
Valdilea Veloso
LJLakshmi Jayashankar
Lakshmi Jayashankar
MTMiriam Tendler
Miriam Tendler

1 May 2008 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
NSNeetu Singh
Neetu Singh
APAseem Pandey
Aseem Pandey
LJLakshmi Jayashankar
Lakshmi Jayashankar
Suresh MittalSuresh Mittal
Suresh Mittal
Because of the high prevalence of adenovirus (Ad) infections in humans, it is believed that pre-existing Ad-neutralizing antibodies (vector immunity) may negatively impact the immune response to vaccine antigens when delivered by human Ad (HAd) vectors. In order to evaluate whether bovine Ad subtype 3 (BAd3), a non-HAd vector, can effectively elude high levels of pre-existing vector immunity, naïve and HAd serotype 5 (HAd)-primed mice were immunized with BAd-H5HA [BAd3 vector expressing the hemagglutinin (HA) gene from H5N1 influenza virus]. Even in the presence of very high levels of HAd-specific neutralizing antibody, no significant reductions in HA-specific humoral and cell-mediated immune (CMI) responses were observed in HAd-primed mice immunized with BAd-H5HA. In naïve mice immunized with HAd-H5HA (HAd5 vector expressing H5N1 HA) and boosted with BAd-H5HA, the humoral responses elicited were significantly higher (P < 0.01) than with either HAd-H5HA or BAd-H5HA alone, while the CMI responses were comparable in the groups. This finding underlines the importance of a heterologous prime-boost approach for achieving an enhanced immune response. The immunization of naïve or HAd-primed mice with BAd-H5HA bestowed full protection from morbidity and mortality following a potentially lethal challenge with A/Hong Kong/483/97. These results demonstrate the importance of BAd vectors as an alternate or supplement to HAd vectors for influenza pandemic preparedness.

18 May 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
OGon behalf of the NIH Tuberculous Meningitis Writing Group
on behalf of the NIH Tuberculous Meningitis Writing Group
SJSanjay Jain
Sanjay Jain
DTDavid M. Tobin
David M. Tobin
ETElizabeth Tucker
Elizabeth Tucker
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman
ZFZsuzsanna Fabry
Zsuzsanna Fabry